Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes

S. M. Lee, H. Yang, Danielle Tartar, B. Gao, X. Luo, S. Q. Ye, H. Zaghouani, D. Fang

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Aims/hypothesis: We recently found that activation of the type III histone deacetylase sirtuin 1 suppresses T cell immune responses. Here we sought to determine the therapeutic potential of the sirtuin 1 activator resveratrol in the treatment of diabetes in the NOD mouse model of type 1 diabetes and the mechanisms underlying such potential. Methods: NOD mice were fed or subcutaneously injected with resveratrol and evaluated for development of diabetes. Splenocytes from resveratrol-treated and control mice were analysed by gene array. The altered expression of inflammatory genes induced by resveratrol was validated and the role of changed gene expression in prevention of diabetes was determined. Results: Resveratrol administration potently prevented and treated type 1 diabetes in NOD mice. Gene array analysis indicated a dramatic decrease in expression of Ccr6, which encodes chemokine (C-C motif) receptor (CCR) 6, in the splenocytes from resveratrol-treated mice. CCR6 abundance on IL-17-producing cells and CD11b+F4/80hi macrophages was inhibited by resveratrol treatment. Interestingly, CCR6+ IL-17-producing cells and CD11b+F4/80hi macrophages accumulated in the spleens and pancreatic lymph nodes, but their presence in the pancreas was reduced, suggesting that resveratrol blocks their migration from peripheral lymphoid organs to the pancreas. Indeed, the migration of splenocytes toward media containing chemokine (C-C motif) ligand 20 (CCL20) was impaired by resveratrol treatment. CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes. Conclusions/interpretation: Inhibition of CCR6-mediated migration of inflammatory cells by resveratrol may provide a powerful approach for treatment of type 1 diabetes and possibly of other inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)1136-1146
Number of pages11
JournalDiabetologia
Volume54
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Inbred NOD Mouse
Sirtuin 1
Interleukin-17
Ligands
Pancreas
CCR Receptors
Histone Deacetylase 1
Macrophages
resveratrol
Gene Expression
CC Chemokines
Genes
Cell Movement
Spleen
Lymph Nodes
T-Lymphocytes
Peptides

Keywords

  • C-C chemokine receptor 6
  • CCR6
  • Disease prevention
  • Resveratrol
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. / Lee, S. M.; Yang, H.; Tartar, Danielle; Gao, B.; Luo, X.; Ye, S. Q.; Zaghouani, H.; Fang, D.

In: Diabetologia, Vol. 54, No. 5, 01.05.2011, p. 1136-1146.

Research output: Contribution to journalArticle

Lee, S. M. ; Yang, H. ; Tartar, Danielle ; Gao, B. ; Luo, X. ; Ye, S. Q. ; Zaghouani, H. ; Fang, D. / Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. In: Diabetologia. 2011 ; Vol. 54, No. 5. pp. 1136-1146.
@article{b9662198da094a08aa620e43afa39fc5,
title = "Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes",
abstract = "Aims/hypothesis: We recently found that activation of the type III histone deacetylase sirtuin 1 suppresses T cell immune responses. Here we sought to determine the therapeutic potential of the sirtuin 1 activator resveratrol in the treatment of diabetes in the NOD mouse model of type 1 diabetes and the mechanisms underlying such potential. Methods: NOD mice were fed or subcutaneously injected with resveratrol and evaluated for development of diabetes. Splenocytes from resveratrol-treated and control mice were analysed by gene array. The altered expression of inflammatory genes induced by resveratrol was validated and the role of changed gene expression in prevention of diabetes was determined. Results: Resveratrol administration potently prevented and treated type 1 diabetes in NOD mice. Gene array analysis indicated a dramatic decrease in expression of Ccr6, which encodes chemokine (C-C motif) receptor (CCR) 6, in the splenocytes from resveratrol-treated mice. CCR6 abundance on IL-17-producing cells and CD11b+F4/80hi macrophages was inhibited by resveratrol treatment. Interestingly, CCR6+ IL-17-producing cells and CD11b+F4/80hi macrophages accumulated in the spleens and pancreatic lymph nodes, but their presence in the pancreas was reduced, suggesting that resveratrol blocks their migration from peripheral lymphoid organs to the pancreas. Indeed, the migration of splenocytes toward media containing chemokine (C-C motif) ligand 20 (CCL20) was impaired by resveratrol treatment. CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes. Conclusions/interpretation: Inhibition of CCR6-mediated migration of inflammatory cells by resveratrol may provide a powerful approach for treatment of type 1 diabetes and possibly of other inflammatory diseases.",
keywords = "C-C chemokine receptor 6, CCR6, Disease prevention, Resveratrol, Type 1 diabetes",
author = "Lee, {S. M.} and H. Yang and Danielle Tartar and B. Gao and X. Luo and Ye, {S. Q.} and H. Zaghouani and D. Fang",
year = "2011",
month = "5",
day = "1",
doi = "10.1007/s00125-011-2064-1",
language = "English (US)",
volume = "54",
pages = "1136--1146",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes

AU - Lee, S. M.

AU - Yang, H.

AU - Tartar, Danielle

AU - Gao, B.

AU - Luo, X.

AU - Ye, S. Q.

AU - Zaghouani, H.

AU - Fang, D.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Aims/hypothesis: We recently found that activation of the type III histone deacetylase sirtuin 1 suppresses T cell immune responses. Here we sought to determine the therapeutic potential of the sirtuin 1 activator resveratrol in the treatment of diabetes in the NOD mouse model of type 1 diabetes and the mechanisms underlying such potential. Methods: NOD mice were fed or subcutaneously injected with resveratrol and evaluated for development of diabetes. Splenocytes from resveratrol-treated and control mice were analysed by gene array. The altered expression of inflammatory genes induced by resveratrol was validated and the role of changed gene expression in prevention of diabetes was determined. Results: Resveratrol administration potently prevented and treated type 1 diabetes in NOD mice. Gene array analysis indicated a dramatic decrease in expression of Ccr6, which encodes chemokine (C-C motif) receptor (CCR) 6, in the splenocytes from resveratrol-treated mice. CCR6 abundance on IL-17-producing cells and CD11b+F4/80hi macrophages was inhibited by resveratrol treatment. Interestingly, CCR6+ IL-17-producing cells and CD11b+F4/80hi macrophages accumulated in the spleens and pancreatic lymph nodes, but their presence in the pancreas was reduced, suggesting that resveratrol blocks their migration from peripheral lymphoid organs to the pancreas. Indeed, the migration of splenocytes toward media containing chemokine (C-C motif) ligand 20 (CCL20) was impaired by resveratrol treatment. CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes. Conclusions/interpretation: Inhibition of CCR6-mediated migration of inflammatory cells by resveratrol may provide a powerful approach for treatment of type 1 diabetes and possibly of other inflammatory diseases.

AB - Aims/hypothesis: We recently found that activation of the type III histone deacetylase sirtuin 1 suppresses T cell immune responses. Here we sought to determine the therapeutic potential of the sirtuin 1 activator resveratrol in the treatment of diabetes in the NOD mouse model of type 1 diabetes and the mechanisms underlying such potential. Methods: NOD mice were fed or subcutaneously injected with resveratrol and evaluated for development of diabetes. Splenocytes from resveratrol-treated and control mice were analysed by gene array. The altered expression of inflammatory genes induced by resveratrol was validated and the role of changed gene expression in prevention of diabetes was determined. Results: Resveratrol administration potently prevented and treated type 1 diabetes in NOD mice. Gene array analysis indicated a dramatic decrease in expression of Ccr6, which encodes chemokine (C-C motif) receptor (CCR) 6, in the splenocytes from resveratrol-treated mice. CCR6 abundance on IL-17-producing cells and CD11b+F4/80hi macrophages was inhibited by resveratrol treatment. Interestingly, CCR6+ IL-17-producing cells and CD11b+F4/80hi macrophages accumulated in the spleens and pancreatic lymph nodes, but their presence in the pancreas was reduced, suggesting that resveratrol blocks their migration from peripheral lymphoid organs to the pancreas. Indeed, the migration of splenocytes toward media containing chemokine (C-C motif) ligand 20 (CCL20) was impaired by resveratrol treatment. CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes. Conclusions/interpretation: Inhibition of CCR6-mediated migration of inflammatory cells by resveratrol may provide a powerful approach for treatment of type 1 diabetes and possibly of other inflammatory diseases.

KW - C-C chemokine receptor 6

KW - CCR6

KW - Disease prevention

KW - Resveratrol

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79954632388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954632388&partnerID=8YFLogxK

U2 - 10.1007/s00125-011-2064-1

DO - 10.1007/s00125-011-2064-1

M3 - Article

C2 - 21340626

AN - SCOPUS:79954632388

VL - 54

SP - 1136

EP - 1146

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 5

ER -